UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/691,570	10/24/2003	Shigeru Nemoto	244406US2	6947

22850   7590   11/17/2010
OBLON, SPIVAK, MCCLELLAND MAIER & NEUSTADT, L.L.P.
1940 DUKE STREET
ALEXANDRIA, VA 22314

EXAMINER
CWERN, JONATHAN

ART UNIT	PAPER NUMBER
3737	

NOTIFICATION DATE	DELIVERY MODE
11/17/2010	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com
oblonpat@oblon.com
jgardner@oblon.com

PTOL-90A (Rev. 04/07)

	Application No.	Applicant(s)
Office Action Summary	10/691,570	NEMOTO, SHIGERU
	Examiner	**Art Unit**	
	Jonathan G. Cwern	3737	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>3</u> MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.
- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on <u>08 October 2010</u>.
2a)☐ This action is **FINAL**.   2b)☒ This action is non-final.
3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) <u>40,41 and 45-49</u> is/are pending in the application.
    4a) Of the above claim(s) _____ is/are withdrawn from consideration.
5)☐ Claim(s) _____ is/are allowed.
6)☒ Claim(s) <u>40,41 and 45-49</u> is/are rejected.
7)☐ Claim(s) _____ is/are objected to.
8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.
10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.
    Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
    Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
    a)☐ All   b)☐ Some * c)☐ None of:
      1.☐ Certified copies of the priority documents have been received.
      2.☐ Certified copies of the priority documents have been received in Application No. _____ .
      3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
    * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☒ Information Disclosure Statement(s) (PTO/SB/08)
    Paper No(s)/Mail Date _____ .
4) ☐ Interview Summary (PTO-413)
    Paper No(s)/Mail Date. _____ .
5) ☐ Notice of Informal Patent Application
6) ☐ Other: _____ .

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set

forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this

application is eligible for continued examination under 37 CFR 1.114, and the fee set

forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action

has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 9/3/10

has been entered.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all

obviousness rejections set forth in this Office action:

> (a) A patent may not be obtained though the invention is not identically disclosed or described as set
> forth in section 102 of this title, if the differences between the subject matter sought to be patented and
> the prior art are such that the subject matter as a whole would have been obvious at the time the
> invention was made to a person having ordinary skill in the art to which said subject matter pertains.
> Patentability shall not be negatived by the manner in which the invention was made.

Claims 40-41 and 45-49 are rejected under 35 U.S.C. 103(a) as being

unpatentable over Uber, III et al. (US 5840026) in view of Duchon et al. (US

2003/0018252), Cherek et al. (US 2004/0081341), and Dahlin et al. (US

2004/0078215).

Uber et al. disclose a patient specific dosing contrast delivery system. The

system first allows for a user to enter patient specific data such as the patient's size and

weight. This data can also be downloaded from an external database. The system

then determines the appropriate concentration of the contrast media, as well as the

appropriate flow rate, volume, time delay, etc. The system also takes into account

imaging parameters such as the section of the body being imaged, and can

automatically adjust based on a desired image quality or sensed amount of

concentration in the body. The concentration of contrast agent can also be adjusted by

adding in a diluent (column 5, line 20-column 6, line 52; column 8, lines 1-7; column 12,

lines 5-26). In general, the system allows for control over many typical imaging and

contrast delivery parameters, and allows for both automated delivery using

predetermined values and also a wide range of user customization if desired. Table 1

(column 8) shows a number of parameters, including length of scanning and duration of

injection. Thus these parameters may be predetermined or selected by the user. Thus,

by using a predetermined length of scanning or duration of the injection, the system

would adjust other values (such as flow rate or injection rate) based on the patient's

specific data (such as size or weight) in order to achieve the desired scan time or

duration of the injection. Different doctors may also have different desired preferences

for these parameters (column 13, lines 30-50), illustrating the amount of customization

the system allows for. Thus each doctor may have a different desired length of

scanning or duration of the injection which they wish to use, and the system can load

this data and adjust other parameters such as injection rate to achieve these goals

taking into account the patient's specific data such as size or weight. Thus a user can

select (or the system can automatically load) the predetermined injection time to be

unchanged and the system will adjust the injection rate based on the user's weight.

One of ordinary skill in the art would recognize that there are wide range of desired

parameters which the system can account for, and use preset values or allow for user customization based on the user's design choice. It would be obvious to one of ordinary skill in the art to customize any of these parameters depending on the specific patient being diagnosed and the user's preferences. Uber et al. fail to show a touch screen user interface.

Duchon et al. disclose an angiographic injector system. Duchon et al. teach a touch screen that is used to select injection parameters ([0022]). Duchon et al. also teach injecting saline ([0074]).

Cherek et al. disclose a method for positioning a patient. Cherek et al. teach a touch screen which displays a patient's body, and scans an area of the patient's body based on which area of the body is selected ([0010]).

Dahlin et al. disclose a system for documenting medical findings. Dahlin et al. teach a touch screen user interface which can display a region of the body, and when an area is selected, can further zoom in to display that area of the body in more detail ([0086]).

It would have been obvious to one of ordinary skill in the art, at the time the invention was made, to have modified the system of Uber et al. to use a touch screen as taught by Duchon et al., as this will provide the user with a simple control over the operation of the system. A variety of different user interfaces could be provided on the touch screen for controlling various portions of the operation, as is well known in the art. Cherek et al. and Dahlin et al. provide specific examples of such user interfaces which could be employed in the combined system of Uber et al. and Duchon et al. Providing

an image of the body for the user to select the desired area being imaged will provide a

simple and intuitive way for the user to select the desired area.

Response to Arguments

Applicant's arguments filed 9/3/10 have been fully considered but they are not

persuasive.

In regards to applicant's arguments that Uber et al. do not show "the

predetermined injection time is unchanged for each said injection of said contrast

medium into a subject", the examiner respectfully disagrees.

In general, the system allows for control over many typical imaging and contrast

delivery parameters, and allows for both automated delivery using predetermined

values and also a wide range of user customization if desired. Table 1 (column 8)

shows a number of parameters, including length of scanning and duration of injection.

Thus these parameters may be predetermined or selected by the user. Thus, by using

a predetermined length of scanning or duration of the injection, the system would adjust

other values (such as flow rate or injection rate) based on the patient's specific data

(such as size or weight) in order to achieve the desired scan time or duration of the

injection. Different doctors may also have different desired preferences for these

parameters (column 13, lines 30-50), illustrating the amount of customization the

system allows for. Thus each doctor may have a different desired length of scanning or

duration of the injection which they wish to use, and the system can load this data and

adjust other parameters such as injection rate to achieve these goals taking into

account the patient's specific data such as size or weight. Thus a user can select (or

the system can automatically load) the predetermined injection time to be unchanged

and the system will adjust the injection rate based on the user's weight. One of ordinary

skill in the art would recognize that there are wide range of desired parameters which

the system can account for, and use preset values or allow for user customization

based on the user's design choice. It would be obvious to one of ordinary skill in the art

to customize any of these parameters depending on the specific patient being

diagnosed and the user's preferences.

Also, applicant refers to "time delay" in the arguments, however the examiner

would note that there are many more time related parameters than merely the "time

delay", of which the examiner has noted above including length of scanning and

duration of the injection. Furthermore, applicant appears to imply that the patient's

weight changing between imaging sessions would negatively impact the quality of the

images, however the examiner would also note that the patient's information would be

updated. That is, the system would not use old data of the patient's weight, as this

would lead to inaccuracies in determining the appropriate amount of contrast agent to

use and other related parameters.

Conclusion

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Jonathan G. Cwern whose telephone number is

(571)270-1560. The examiner can normally be reached on Monday through Friday 9:30AM - 6:00PM EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brian Casler can be reached on 571-272-4956. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Jonathan G Cwern/   /BRIAN CASLER/
Examiner, Art Unit 3737   Supervisory Patent Examiner, Art
                                                      Unit 3737